StockTipsArenaBeta

BUY SYMBIOTEC PHARMALAB LTD — Motilal Oswal

BUYSYMBIOTEC PHARMALAB LTD
SYMBIOTEC PHARMALAB share price target & all analyst calls

byMotilal OswalHorizon: NA (inferred 1 year)26 Oct 2026via ET Now (Live)

Entry₹1,212.45Inferred
Target₹1,430
Total upside +17.94%
Stop lossNot given
CMP₹1,229.8Just now
Active+1.43%+16.28%upside left 12 mo left
Follow Motilal Oswal for new calls(62% target hit, 1113 closed calls)Get alertsWatch SYMBIOTEC for new buy/sell callsGet alertsSee 1 other Long-term call on SYMBIOTECSee 80 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 4:42 pm IST
4 supporting5 neutral0 opposing
Supports the BUY call (4)

Broker’s call: Symbiotec Pharmalab (Buy)

NewsHbl·1 Oct · 3w ago

(opens in new tab)

Symbiotec's subsidiary, Knovea Pharmaceutical, signed a strategic commercialization agreement with a global pharmaceutical company for Dual Chamber Vials.

BSE · Company Update·30 Sept · 4w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·1 Oct · 4w ago

Symbiotec Pharma shares jump 8% after US FDA report on Pithampur plant

NewsCnbc-Tv18·29 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (5)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on SYMBIOTEC PHARMALAB

All analyst calls on SYMBIOTEC PHARMALAB

More from Motilal Oswal

Every call and its outcome